MedTrace Logo

Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

NCT00420303 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-07-20

Study results available
· View outcomes & findings →

Summary

To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.

Conditions

  • Spondylarthropathies, Enthesitis

Interventions

DRUG

Etanercept

50 mg injection once weekly

OTHER

Placebo

placebo

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • France
  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420303 on ClinicalTrials.gov